Analysts at Jefferies Financial Group assumed coverage on shares of Cybin (NASDAQ:HELP – Get Free Report) in a report released on Monday. The brokerage set a “buy” rating and a $22.00 price target on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 232.33% from the company’s current price.
Cybin Price Performance
Shares of NASDAQ:HELP opened at $6.62 on Monday. The stock has a market cap of $330.27 million, a price-to-earnings ratio of -1.70 and a beta of 0.63. Cybin has a 1-year low of $4.81 and a 1-year high of $10.72. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.58 and a quick ratio of 8.58.
Cybin Company Profile
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
See Also
- Five stocks we like better than Cybin
- Trump just signed it
- Trump Devises the Death of the IRS ??
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- GOLD ALERT
- What Expenses Can Be Deducted From Capital Gains Tax?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
